- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fujimori named to lead GEMS Asia
GE has shifted its executive lineup in Asia, promoting Goran Malm to president of GE Asia-Pacific and naming Yoshiaki Fujimori to assume Malm's position as president and CEO of GE Medical Systems Asia. Fujimori was previously general manager of global
GE has shifted its executive lineup in Asia, promoting Goran Malm to president of GE Asia-Pacific and naming Yoshiaki Fujimori to assume Malm's position as president and CEO of GE Medical Systems Asia. Fujimori was previously general manager of global MRI, nuclear medicine, and PET at GE Medical Systems in Milwaukee.
Malm is credited with orchestrating the expansion of GEMS in a broad geographic region that ranges from Japan to Australia to India. In his new capacity, Malm will lead GE's international activities in the Asia-Pacific region.
Fujimori credited the MRI product development group's ability to bring new systems to market as a key to his elevation. This is Fujimori's second Asian tour of duty: He was manager of business development for GE Medical Systems Asia in 1990 when he was transferred to Milwaukee as general manager of nuclear medicine. In 1992, he was named manager of CT and radiation therapy. In February 1996, the company announced his appointment as global general manager of MRI operations.
Succeeding Fujimori as general manager of global MRI is Gene Saragnese, who was transferred to Milwaukee in late 1995 as manager of MR engineering. Fujimori's managerial duties over nuclear medicine and PET in Milwaukee were delegated to Sharon Banaszewski, who was promoted to general manager of the nuclear medicine/PET group.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
